1. Home
  2. INDP vs SRG Comparison

INDP vs SRG Comparison

Compare INDP & SRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$3.93

Market Cap

125.2M

Sector

Health Care

ML Signal

HOLD

Logo Seritage Growth Properties

SRG

Seritage Growth Properties

HOLD

Current Price

$1.96

Market Cap

146.4M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
INDP
SRG
Founded
2000
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
125.2M
146.4M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
INDP
SRG
Price
$3.93
$1.96
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.9M
180.0K
Earning Date
05-11-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
53.90
EPS
N/A
N/A
Revenue
N/A
$18,204,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
3.30
52 Week Low
$0.92
$1.86
52 Week High
$8.57
$4.38

Technical Indicators

Market Signals
Indicator
INDP
SRG
Relative Strength Index (RSI) 78.02 33.53
Support Level $1.73 $1.86
Resistance Level $4.94 $2.18
Average True Range (ATR) 0.41 0.08
MACD 0.29 0.00
Stochastic Oscillator 94.12 20.31

Price Performance

Historical Comparison
INDP
SRG

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

About SRG Seritage Growth Properties

Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, sale, and leasing of diversified retail and mixed-use properties throughout the United States.

Share on Social Networks: